Home » Stocks » VBIV

VBI Vaccines, Inc. (VBIV)

Stock Price: $3.23 USD 0.01 (0.16%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $3.23 +0.01 (0.16%) Jan 15, 7:59 PM
Market Cap 780.62M
Revenue (ttm) 1.47M
Net Income (ttm) -41.74M
Shares Out 234.71M
EPS (ttm) -0.21
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $3.23
Previous Close $3.22
Change ($) 0.01
Change (%) 0.16%
Day's Open 3.39
Day's Range 3.22 - 3.88
Day's Volume 25,723,374
52-Week Range 0.73 - 6.17

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Benzinga - 2 days ago

Esperion Therapeutics (NASDAQ: ESPR) shares are trading lower after Bank of America Securities downgraded the stock from Buy to Neutral and announced a price target of $35 per share. Esprit Ho...

Other stocks mentioned: ESPR, NVS
The Motley Fool - 2 days ago

The company reported good news from a study of its hepatitis B vaccine.

Business Wire - 2 days ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

InvestorPlace - 6 days ago

With risk-return not in your favor, steer clear of these 8 penny stocks, all of which could see big declines as the new year unfolds. Chesapeake Energy (OTCMKTS:CHKAQ) Genius Brands (NASDAQ:GN...

Other stocks mentioned: CHKAQ, GNUS, HTZGQ, MARK, OCGN, STON, XSPA
Business Wire - 3 weeks ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 1 month ago

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

Business Wire - 1 month ago

CAMBRIDGE, Mass. & MORRISVILLE, N.C.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company developing next-generation infectious disease and immuno-on...

Other stocks mentioned: SYNH
Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 1 month ago

VBI Vaccines' (VBIV) early-stage hepatitis B virus immunotherapeutic candidate, VBI-2601, achieves promising immune response in patients on interim analysis.

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-onco...

Business Wire - 1 month ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 2 months ago

Investors need to pay close attention to VBI Vaccines (VBIV) stock based on the movements in the options market lately.

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

The Motley Fool - 2 months ago

"Buy low, sell high" is easy when stocks are cheap. The hard part is finding inexpensive healthcare stocks that are more than just speculative trades.

Other stocks mentioned: APTX, SELB
Business Wire - 2 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

The Motley Fool - 2 months ago

Here's why investors should stay away from some of the riskiest coronavirus stocks on the market.

Other stocks mentioned: SRNE, VXRT
The Motley Fool - 2 months ago

Neither biotech is in the front of the pack in developing a COVID-19 vaccine.

Other stocks mentioned: INO
InvestorPlace - 3 months ago

It wasn't just toilet paper that was in demand when Covid-19 hit us as short-term stocks flew through the roof. But with a second wave upon us, this narrative looks very compelling.

Other stocks mentioned: AMWL, BABA, GME, IFRX, SNE, SWBI
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 3 months ago

In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.95, marking a +0.68% move from the previous day.

The Motley Fool - 3 months ago

In the race for a vaccine, a pause in progress sets you back.

Other stocks mentioned: ALT, CVAC
Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 3 months ago

In the latest trading session, VBI Vaccines, Inc. (VBIV) closed at $2.98, marking a +0.68% move from the previous day.

Business Wire - 3 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncol...

Zacks Investment Research - 4 months ago

VBI Vaccines, Inc. (VBIV) closed the most recent trading day at $3.76, making no change from the previous trading session.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

The Motley Fool - 4 months ago

The biotech will present additional data for one of its pipeline candidates later this week.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

Zacks Investment Research - 4 months ago

VBI Vaccines, Inc. (VBIV) closed at $3.12 in the latest trading session, marking a +0.65% move from the prior day.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

The Motley Fool - 4 months ago

Investors who are looking for promising coronavirus vaccine stocks should keep an eye out for this emerging biotech.

Zacks Investment Research - 4 months ago

VBI Vaccines (VBIV) selects two coronavirus vaccine candidates for clinical-stage development based on encouraging pre-clinical data.

The Motley Fool - 4 months ago

Pre-clinical results indicate that both are effective in only single doses.

Benzinga - 4 months ago

Shares of VBI Vaccines Inc (NASDAQ: VBIV) are moving strongly to the upside Thursday.

The Motley Fool - 4 months ago

Investors are fired up about an analyst's enthusiastic upgrade of the biotech stock.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

The Motley Fool - 4 months ago

The potential rewards with this biotech stock are high, but so are the risks.

Business Wire - 4 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

The Motley Fool - 4 months ago

If you're hoping this biotech will win big with its coronavirus vaccine candidate, you may be looking in the wrong place.

Business Wire - 4 months ago

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Therapure Biomanufacturing, a division of Therapure Biopharma Inc., announced today the signing of an agreement with VBI Vaccines Inc.

Business Wire - 5 months ago

OTTAWA, Ontario & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--Variation Biotechnologies Inc.

Zacks Investment Research - 5 months ago

VBI Vaccines, Inc. (VBIV) delivered earnings and revenue surprises of 20.00% and -78.48%, respectively, for the quarter ended June 2020.

Business Wire - 5 months ago

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $VBIV--VBI Vaccines Inc.

The Motley Fool - 5 months ago

One biotech keeps making headlines, the other's much quieter. But both have been big gainers, and both have strong potential opportunities.

Other stocks mentioned: MRNA
The Motley Fool - 5 months ago

A sell-off that began last week continues.

Zacks Investment Research - 5 months ago

VBI Vaccine (VBIV) will provide financial updates when it releases second-quarter 2020 results.

About VBIV

VBI Vaccines, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology in Israel, the United States, and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for a functional cure of chronic hepatitis B. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the ... [Read more...]

Industry
Biotechnology
CEO
Jeffrey R. Baxter F.C.M.A., FCMA
Employees
123
Stock Exchange
NASDAQ
Ticker Symbol
VBIV
Full Company Profile

Financial Performance

In 2019, VBI Vaccines's revenue was $2.22 million, a decrease of -33.80% compared to the previous year's $3.36 million. Losses were -$54.81 million, -13.82% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for VBI Vaccines stock is "Strong Buy." The 12-month stock price forecast is 6.50, which is an increase of 101.55% from the latest price.

Price Target
$6.50
(101.55% upside)
Analyst Consensus: Strong Buy